Johnson & Johnson (NYSE:JNJ) Price Target Raised to $237.00

Johnson & Johnson (NYSE:JNJ) had its target price raised by analysts at Daiwa Capital Markets from $203.00 to $237.00 in a research report issued on Thursday,MarketScreener reports. The firm presently has an “outperform” rating on the stock. Daiwa Capital Markets’ target price would indicate a potential upside of 4.81% from the company’s current price.

A number of other research firms also recently issued reports on JNJ. Weiss Ratings reiterated a “buy (b)” rating on shares of Johnson & Johnson in a research report on Wednesday. Wall Street Zen raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Sunday, January 25th. Wolfe Research boosted their target price on shares of Johnson & Johnson from $225.00 to $240.00 and gave the stock an “outperform” rating in a research report on Monday, January 5th. Stifel Nicolaus raised their price target on shares of Johnson & Johnson from $205.00 to $220.00 and gave the company a “hold” rating in a research report on Thursday, January 22nd. Finally, Wells Fargo & Company boosted their price objective on Johnson & Johnson from $230.00 to $240.00 and gave the stock an “overweight” rating in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average price target of $231.91.

Johnson & Johnson Price Performance

Shares of NYSE JNJ traded down $1.16 during midday trading on Thursday, reaching $226.13. 499,658 shares of the company were exchanged, compared to its average volume of 9,024,039. The stock’s 50-day moving average price is $210.25 and its 200-day moving average price is $190.83. Johnson & Johnson has a one year low of $141.50 and a one year high of $230.00. The stock has a market cap of $544.81 billion, a P/E ratio of 20.50, a PEG ratio of 2.21 and a beta of 0.34. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, January 21st. The company reported $2.46 earnings per share (EPS) for the quarter, meeting the consensus estimate of $2.46. The firm had revenue of $24.56 billion during the quarter, compared to analysts’ expectations of $24.14 billion. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.34%. The company’s revenue was up 9.1% on a year-over-year basis. During the same period in the prior year, the company posted $2.04 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.430-11.630 EPS. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Institutional Trading of Johnson & Johnson

Institutional investors and hedge funds have recently bought and sold shares of the company. Abich Financial Wealth Management LLC bought a new position in Johnson & Johnson in the third quarter valued at $26,000. Evolution Wealth Management Inc. purchased a new position in Johnson & Johnson in the 2nd quarter worth $27,000. Clayton Financial Group LLC purchased a new stake in Johnson & Johnson during the third quarter valued at about $28,000. DecisionPoint Financial LLC increased its holdings in shares of Johnson & Johnson by 104.2% in the fourth quarter. DecisionPoint Financial LLC now owns 147 shares of the company’s stock worth $30,000 after buying an additional 75 shares during the period. Finally, Family CFO Inc bought a new stake in shares of Johnson & Johnson in the 4th quarter valued at about $31,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: CHMP gives positive opinion on AKEEGA (niraparib + abiraterone) for BRCA1/2 mHSPC — a potential new standard-of-care that expands J&J’s oncology franchise and supports longer-term revenue upside. Article Title
• Positive Sentiment: Morgan Stanley upgraded JNJ on improved growth outlook; multiple outlets report the upgrade and the stock reaction — analyst upgrades are driving buying interest and helped push JNJ toward a fresh annual peak. Article Title
• Positive Sentiment: Scotiabank raised its price target to $265 (from $230) after a strong quarter and reiterated Outperform — further analyst target lifts add credibility to the rally. Article Title
• Positive Sentiment: US judge dismissed a lawsuit alleging J&J committed fraud over use of a shell-company bankruptcy related to talc litigation — removes a legal overhang and lowers tail risk for investors. Article Title
• Neutral Sentiment: Q4 results: J&J met EPS, beat revenue and gave FY2026 EPS guidance (11.43–11.63) and sales guidance ~ $100–101B — fundamentals support the re-rating but some analysts still view upside as measured. Article Title
• Neutral Sentiment: Options volume is unusually high — can signal elevated speculative/hedge activity but not a directional catalyst by itself. Article Title
• Negative Sentiment: JNJ CEO Joaquin Duato sold ~$22M of stock post-Q4 — large insider sales can spook traders even if filings show routine diversification; worth monitoring for follow-up. Article Title
• Neutral Sentiment: Positive mentions from fund managers and analyst blogs (Barron’s, Zacks, Seeking Alpha) add investor interest but are reiterative rather than new fundamental news. Article Title

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.